HOUSTON -- A novel self-administered shot that inhibits two key immunoregulatory cytokines reduced proteinuria in patients ...

Positive autoantibodies rates are lower among patients with dermatomyositis who take immunostimulatory herbs than, compared ...

The safety profile of atacicept across the ORIGIN program appears favorable, and comparable to placebo Biologics License Application (BLA) submission through the Accelerated Approval Program to the U.

PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation ...

Elevated autoantibodies against incretin hormones may indicate poorer outcomes in diabetes, highlighting potential for new ...

On 4 November, the European Diabetes Forum (EUDF) and EDENT1FI (European Action for the Diagnosis of Early Non-clinical Type ...

ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral ...

A new consensus report on the management of type 1 diabetes in adults was presented recently at the European Association for ...

Celltrion will develop and commercialize Kaigene's nonclinical-stage antibody assets, KG006 and KG002, under an exclusive licensing agreement. -- Kaigene will receive $8M upfront payment and up to ...

A new approach targets the B-cell pathway with bispecific antibodies, building on decades of research that establishes the ...

CHICAGO >> President Donald Trump’s embrace of an old generic drug called leucovorin for use against a rare disorder that causes autism-like symptoms has triggered a surge in demand from parents who ...

U.S. President Donald Trump's embrace of an old generic drug called leucovorin for use against a rare disorder that causes ...